Patents by Inventor Mohammed Sharief

Mohammed Sharief has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120142775
    Abstract: A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of ?-linolenic acid, dihomo-?-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-?1 levels in the patient to therapeutic levels.
    Type: Application
    Filed: February 1, 2012
    Publication date: June 7, 2012
    Applicant: BTG International Limited
    Inventors: Laurence S. Harbige, Michael J. Leach, Mohammed Sharief, Paul Barraclough
  • Publication number: 20110184063
    Abstract: A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a triglyceride oil containing both ?-linolenic acid and linoleic acid residues as triglyceride ester, the ratio of ?-linolenic acid to linoleic acid residues at the sn-2 position of the triglyceride being at least 0.8; the amount of ?-linolenic acid residues at the sn-2 position being at least 18%, wherein the oil is administered at a dose sufficient to maintain or elevate TGF-?1 levels in the patient at a therapeutic level. Preferably the method is that wherein the therapeutic level is such as to produce a TGF-?1/TNF-? ratio of at least 0.5 in blood of a patient, after 18 months of daily dosing. Preferred oils are Borage or Mucor oils having at least 35% of the sn-2 position fatty acid residues as ?-linolenic acid.
    Type: Application
    Filed: April 6, 2011
    Publication date: July 28, 2011
    Applicant: BTG International Limited
    Inventors: Laurence S. Harbige, Michael J. Leach, Mohammed Sharief
  • Patent number: 7964641
    Abstract: A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of ?-linolenic acid, dihomo-?-linolenic acid and arachidonic acid characterized in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-?1 levels in the patient to therapeutic levels.
    Type: Grant
    Filed: August 13, 2004
    Date of Patent: June 21, 2011
    Assignee: BTG International Limited
    Inventors: Laurence S. Harbige, Michael J. Leach, Mohammed Sharief, Paul Barraclough
  • Patent number: 7935729
    Abstract: Method for treating a patient in need of therapy for a neurodegenerative disease by administering to that patient a therapeutically effective dose of a triglyceride oil containing both ?-linolenic acid and linolenic acid residues as triglyceride ester. The ratio of ?-linolenic acid to linolenic acid residues at the sn-2 position of the triglyceride is at least 0.8. The amount of ?-linolenic acid residues at the sn-2 position is at least 18%. The oil is administered at a dose sufficient to maintain or elevate TGF-?1 levels in the patient at a therapeutic level.
    Type: Grant
    Filed: May 14, 2004
    Date of Patent: May 3, 2011
    Assignee: BTG International Limited
    Inventors: Laurence S. Harbige, Michael J. Leach, Mohammed Sharief
  • Publication number: 20100113595
    Abstract: A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of ?-linolenic acid, dihomo-?-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-?1 levels in the patient to therapeutic levels.
    Type: Application
    Filed: December 31, 2009
    Publication date: May 6, 2010
    Applicant: BTG International Limited
    Inventors: Lawrence S. Harbige, Michael J. Leach, Mohammed Sharief, Paul Barraclough
  • Publication number: 20100113810
    Abstract: A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of ?-linolenic acid, dihomo-?-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-?1 levels in the patient to therapeutic levels.
    Type: Application
    Filed: December 31, 2009
    Publication date: May 6, 2010
    Applicant: BTG International Limited
    Inventors: Laurence S. Harbige, Michael J. Leach, Mohammed Sharief, Paul Barraclough
  • Publication number: 20090036410
    Abstract: A method of treating a patient in need of therapy for a disease in which cyokines have become dysregulated, or are otherwise capable of modulation to provide therapeutic benefit, is provided comprising administering to that patient a therapeutically effective dose of a phospholipid comprising a phosphatidyl group esterifed with one or more fatty acyl groups, characterised in that the phospholipid has at least one fatty acyl group at the sn-1 and/or sn-2 position of the phosphatidyl group, the fatty acyl group being selected from the group consisting of ?-linolenoyl, dihomo-?-linolenoyl acid and arachidonoyl.
    Type: Application
    Filed: November 25, 2005
    Publication date: February 5, 2009
    Applicant: BTG INTERNATIONAL LIMITED
    Inventors: Laurence S. Harbige, Michael J. Leach, Mohammed Sharief, Paul Barraclough
  • Publication number: 20080194684
    Abstract: A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of ?-linolenic acid, dihomo-?-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-? levels in the patient to therapeutic levels.
    Type: Application
    Filed: August 13, 2004
    Publication date: August 14, 2008
    Applicant: BTG International Limited
    Inventors: Laurence S. Harbige, Michael J. Leach, Mohammed Sharief, Paul Barraclough
  • Publication number: 20080090908
    Abstract: A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a triglyceride oil containing both ?-linolenic acid and linolenic acid residues as triglyceride ester, the ratio of ?-linolenic acid to linolenic acid residues at the sn-2 position of the triglyceride being at least 0.8; the amount of ?-linolenic acid residues at the sn-2 position being at least 18%, wherein the oil is administered at a dose sufficient to maintain or elevate TGF-?1 levels in the patient at a therapeutic level. Preferably the method is that wherein the therapeutic level is such as to produce a TGF-?1/TNF-? ratio of at least 0.5 in blood of a patient, after 18 months of daily dosing. Preferred oils are Borage or Mucor oils having at least 35% of the sn-2 position fatty acid residues as ?-linolenic acid.
    Type: Application
    Filed: May 14, 2004
    Publication date: April 17, 2008
    Applicant: BTG INTERNATIONAL LIMITED
    Inventors: Laurence S. Harbige, Michael J. Leach, Mohammed Sharief
  • Publication number: 20040229873
    Abstract: A method of treating a patient in need of therapy for multiple sclerosis is provided, comprising administering to that patient a therapeutically effective dose of a compound of formula I 1
    Type: Application
    Filed: January 14, 2004
    Publication date: November 18, 2004
    Applicant: BTG International Limited
    Inventors: Laurence S. Harbige, Michael J. Leach, Mohammed Sharief